Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT

Bone Marrow Transplantation

Volumn 45, Issue 1, 2010, Pages 123-127

  Musso, M ^a   Scalone, R ^a   Crescimanno, A ^a   Bonanno, V ^a   Polizzi, V ^a   Porretto, F ^a   Bianchini, C ^b   Perrone, T ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b Scientific Department   (Italy)

Author keywords

5 HT3 antagonist; Antiemetics; Autologous stem cell transplantation; Chemotherapyinduced nausea and vomiting (CINV); Palonosetron

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FOTEMUSTINE; IDARUBICIN; MELPHALAN; PALONOSETRON;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FEMALE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETREATMENT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VOMITING;

EID: 75149196366     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.114     Document Type: Article

References (35)

1. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109.
2. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patient with cancer. J Clin Oncol 1997; 15: 116-123. (Pubitemid 27020564)
3. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005; 13: 219-227.
4. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of post-chemotherapy nausea and vomiting on health related quality of life. Support Care Cancer 1997; 5: 307-313.
5. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M et al. Prevention of DHAP-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus DHAP. J Clin Oncol 1991; 9: 675-678.
6. Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E et al. DHAP improves the efficacy of granisetron in the first 24 h following high-dose DHAP chemotherapy. Support Care Cancer 1995; 3: 307-312.
7. Carmichael J, Bessell EM, Harris AL, Hutcheon AW, Dawes PJ, Daniels S et al. Comparison of granisetron alone and granisetron plus DHAP in the prophylaxis of cytotoxicinduced emesis. Br J Cancer 1994; 70: 1161-1164.
8. The Italian Group for Antiemetic Research. DHAP, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
9. The Italian Group for Antiemetic Research. Ondansetron vs metoclopramide, both combined with DHAP, in the prevention of DHAP-induced delayed emesis. J Clin Oncol 1997; 15: 124-130.
10. Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with DHAP in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003; 14: 291-297.
11. Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP. The role of the 5-HT3 antagonist ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1997; 8: 181-185.
12. Italian Group for Antiemetic Research. DHAP alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-1559.
13. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a doubleblind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
14. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5- HT3 receptor antagonist: results of a phase III, single dose trial vs dolasetron. Cancer 2003; 98: 2473-2482.
15. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following higly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
16. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced, nausea and vomiting: a multinational, randomized, double-blind, placebo- controlled trial in patients receiving high-dose DHAP- The aprepitant protocol 052 study group. J Clin Oncol 2003; 21: 4112-4119.
17. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of the chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 3090-3098.
18. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with DHAP, for antiemetic efficacy in high-dose DHAP treatment. Ann Oncol 2006; 17: 1000-1006.
19. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-5851.
20. Sledge Jr GW, Einhorn L, Nagy C, House K. Phase III double-blind comparison of i.v. ondansetron and metoclopramide for patients receiving multiple-day DHAP based chemotherapy. Cancer 1992; 70: 2524-2528.
21. Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG. A double-blind, randomised crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety, and patient preference. The Granisetron Study Group. Eur J Cancer 1994; 30A: 1083-1088.
22. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A. Ondansetron vs ondansetron, DHAP, and chlopromazine in the prevention of nausea and vomiting associated with multipleday DHAP chemotherapy. J Clin Oncol 1993; 11: 2391-2395.
23. Fauser AA, Pizzocaro G, Schueller J, Khayat D, Wilkinson P. A double-blind, randomised, parallel study comparing i.v. dolasetron plus DHAP and i.v. dolasetron alone for the management of fractionated DHAP-related nausea and vomiting. Support Care Cancer 2000; 8: 49-54.
24. Viner CV, Selby PJ, Zulian GB, Gore ME, Butcher ME, Wootton CM et al. Ondansetron-a new safe and effective antiemetic in patient receiving high-dose melphalan. Cancer Chemother Pharmacol 1990; 25: 449-453.
25. Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5HT3 regimen and literature review. Support Care Cancer 1999; 7: 414-424.
26. Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R. Antiemetic efficacy of granisetron plus DHAP in BM transplant patients receiving chemotherapy and TBI. BM Transplant 1999; 23: 265-269.
27. Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K et al. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. BM Transplant 2001; 28: 1061-1066.
28. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen Jr MT, Bubalo J. Palonosetron plus DHAP for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day DHAP chemotherapy for germ cell cancer. Support Care Cancer 2007; 15: 1293-1300.
29. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F et al. Palonosetron (Aloxi) and DHAP for prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 2009; 17: 205-209.
30. Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995; 114: 851-859.
31. Navari RM. Prevention of emesis from multiple-day and highdose chemotherapy regimens. J Natl Compr Canc Netw 2007; 5: 51-59.
32. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947.
33. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
34. Ló pez-Jiménez J, Martín-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006; 91: 84-91.
35. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analag 2008; 107: 469-478.